Mode
Text Size
Log in / Sign up
N/A Completed N=485 Randomized Treatment

Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy

Source: ClinicalTrials.gov NCT00417989 ↗
Enrolled (actual)
485
Serious AEs
12.8%
Results posted
Mar 2011
Primary outcomePrimary: Change in A1c From Baseline to 52 Weeks — -0.8; -0.2 Percent glycated hemoglobin — p=0.05

Summary

Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group". Secondary Outcomes: Incidence and frequency of severe hypoglycemia; Measure of glycemic variability, Area Under the Curve (AUC); Quality of Life; and Health Economic Outcomes (MRU)

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in A1c From Baseline to 52 Weeks
-0.8; -0.2 0.05
SECONDARY
Difference in Frequency of Severe Hypoglycemia From Baseline to Week 52;
32; 27 —
SECONDARY
Overall Difference in Rate of Severe Hypoglycemia Events Between Study Arms From Baseline to Week 52
21; 17 0.84
SECONDARY
Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 52;
0.0; 0.0 0.05
SECONDARY
Changes From Baseline in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 52
-11.9; -1.1 0.05
SECONDARY
Quality of Life - Hypoglycemia Fear Scale (HFS), Overall Score
-9.0; -2.4 < 0.001 sig
SECONDARY
Health Economic Outcome
10,760; 5,072 —
SECONDARY
Quality of Life - Short Form-36 (SF-36v2™), General Health
2.7; -0.3 —
SECONDARY
Quality of Life - Insulin Delivery System Rating Questionnaire (IDSRQ) for Subject Satisfaction With Type of Insulin Therapy
18.4; -0.2 —

Eligibility Criteria

Inclusion Criteria

  • Aged 7 to 70 years
  • Has been treated by the Principal Investigator or referring physician within the same practice for at least six months prior to screening
  • Is fluent in speaking, reading and understanding English
  • Has Type 1 diabetes mellitus, diagnosed by c-peptide, insulin antibodies, or prior documented DKA, or by a clinical picture consistent with Type 1 diabetes and excluding type 2 diabetes i.e. - previous ketosis as evidenced by laboratory evidence of urine ketones or alteration in bicarbonate levels with corresponding increased glucose levels, diagnosed at least 6 months prior to study entry, or has a fasting C-peptide that meet criteria of 110% of lower limit of normal or 200% of lower limit of normal in the presence of renal insufficiency (creatinine clearance (greater or equal to) three (3) times daily and therapy has included the use of a long acting analog insulin for at least the previous 3 months prior to screening
  • Performs fingerstick blood glucose (BG) testing an average of four times per day in the 30 days prior to screening
  • Within 6 months prior to study entry and at Screening Visit 1, subject has a documented A1c level =/> 7.4% and =/ 100 mmHg and/or sustained systolic level [3 successive readings] > 160). Subjects who are taking antihypertensive medication will not be excluded provided they are maintained at a stable dose for 3 months prior to screening
  • Has serious or unstable medical or psychological conditions (e.g., eating disorders, clinical depression, anxiety disorder) which, in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study
  • Is undergoing renal dialysis, including hemodialysis and continuous ambulatory peritoneal dialysis (CAPD)
  • Has evidence of any allergic dermatological condition (e.g., severe adhesive sensitivity)
  • Has recurrent episodes of skin infections or history of staphylococcus infection carrier state
  • Has potential for lack of compliance or any other issue that may preclude the subject from satisfactory participation in the study, based on Investigatory judgment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00417989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search